2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-120059
    NS4591 273930-52-2 98%
    NS4591 is a modulator of calcium-activated potassium channels with activity that enhances small (SK) and intermediate (IK) conductivity. NS4591 doubled IK-mediated currents in whole-cell patch-clamp experiments at a concentration of 45 +/- 6 nM, and doubled SK3-mediated currents at a concentration of 530 +/- 100 nM. NS4591 inhibits the number of action potentials generated by suprathreshold depolarizing pulses in acutely isolated bladder primary afferent neurons. NS4591 also reduced carbakol-induced detrusor ring contraction in the rat bladder, demonstrating sensitivity to apamin.
    NS4591
  • HY-120068
    VU0418506 1330624-42-4 98%
    VU0418506 is a selective positive allosteric modulator of mGlu4, with EC50 values of 68 nM and 46 nM for hmGlu4 and rmGlu4, respectively. VU0418506 exhibits antiparkinsonian activity.
    VU0418506
  • HY-120076
    CP-293019 179089-90-8 98%
    CP-293019 is a dopamine D4 receptor antagonist, with a Ki value of 3.4 nM. CP-293019 can inhibit Apomorphine (HY-12723) induced hyperactivity in rats.
    CP-293019
  • HY-120081
    Metixene 4969-02-2 98%
    Metixene (Piperidine) is an anticholinergic and antiparkinsonian agent. Metixene potently inhibits binding of quinuclidinyl benzilate (QNB) with the muscarinic receptor, IC50 and Ki values of 55 nM and 15 nM, respectively. Metixene can be used for the research of parkinsonian.
    Metixene
  • HY-120096
    BIBO3304 free base 191868-13-0 98%
    BIBO3304 free base is a nonpeptide neuropeptide Y Y1 receptor antagonist. BIBO3304 free base displays subnanomolar affinity for both the human and the rat Y1 receptor, with IC50 values of 0.38 nM and 0.72 nM, respectively. BIBO3304 free base significantly inhibits food intake induced by application of NPY or by fasting.
    BIBO3304 free base
  • HY-120128
    MTSEA hydrobromide 16599-33-0
    MTSEA hydrobromide is a sulfhydryl-reactive compound that modifies free cysteine residues to produce a positively charged side chain approximately the size of lysine.
    MTSEA hydrobromide
  • HY-120144
    SR-8993 1594121-16-0 98%
    SR-8993 is a highly selective nociceptin receptor agonist that can penetrate the blood-brain barrier and has the activity of reducing alcohol intake and relieving withdrawal anxiety. SR-8993 has shown mild anxiolytic effects in animal models and can effectively reverse anxiety caused by acute alcohol withdrawal. SR-8993 further reduces restricted drinking, operant responses for alcohol, and increased drinking induced by long-term intermittent exposure to alcohol. SR-8993 also reduces stress- and cue-related alcohol-seeking relapse.
    SR-8993
  • HY-120146
    NNC 05-2090 184845-43-0 98%
    NNC 05-2090 is aGABA uptake inhibitor and inhibitor of the β-GABA transporter (BGT-1) (IC50 sub>: 10.6 μM). NNC 05-2090 also inhibits mGAT2 with a Ki value of 1.4 μM. NNC 05-2090 has anticonvulsant activity and can be used in the study of epilepsy and neurological diseases.
    NNC 05-2090
  • HY-120158
    ZD0947 172649-40-0 98%
    ZD0947 is an ATP-sensitive potassium channel activator with relatively effective activation of smooth muscle KATP channels (SUR2B/Kir6.1 and SUR2B/Kir6.2). ZD0947 partially antagonizes pancreatic KATP channels (SUR1/Kir6.2) and cardiac KATP channels (SUR2A/Kir6.2). ZD0947 is potentially used to inhibit overactive bladder (OAB).
    ZD0947
  • HY-120167
    YM-44778 173941-74-7 98%
    YM-44778 is a neurokinin receptor antagonist. The pKi values for NK1, NK2 and NK3 are 8.08, 8.55 and 8.24, respectively. YM-44778 inhibits the increase of bladder pressure induced by substance [Sar9,Met(O2)11] -P (HY-P1012) in anestheticized rats.
    YM-44778
  • HY-120189
    LY 233536 136845-59-5 98%
    LY 233536 is a competitive NMDA receptor antagonist.
    LY 233536
  • HY-120229
    GGTI-2147 191102-87-1 98%
    GGTI-2147 is a potent GGTase I inhibitor. GGTI-2147 blocks geranyl-geranylation of Rap1A and reduces the activity of Rac1 (one of substrates for GGTI) and ameliorates the OGD/R-induced neuronal apoptosis.GGTI-2147 can be used for neurodevelopmental disorders research, such as autism, depression, and schizophrenia.
    GGTI-2147
  • HY-120236
    KSCM-5 1415247-18-5 98%
    KSCM-5 is a sigma receptor ligand with high affinity activity on sigma-1 receptor. The Ki value of KSCM-5 is about 34nM, showing significant selectivity. KSCM-5 has potential application value in compound development, especially for diseases related to sigma receptors.
    KSCM-5
  • HY-120239
    Ro 63-0563 202466-77-1 98%
    Ro 63-0563 is a potent, competitive and selective 5-HT6 receptor antagonist with pKi values of 7.83 and 7.91 for rat and human 5-HT6 receptors, respectively. Ro 63-0563 has no affinity for other receptors.
    Ro 63-0563
  • HY-120243
    L-Ibotenic acid 25690-45-3 98%
    L-Ibotenic acid is a psychoactive compound found in Amanita muscaria and related mushroom species. L-Ibotenic acid is a conformationally restricted analog of the neurotransmitter glutamate, which may be activated by different conformations of L-glutamate and is a non-selective glutamate receptor agonist.
    L-Ibotenic acid
  • HY-120251
    Leteprinim 138117-50-7 98%
    Leteprinim (AIT-082 free acid), a purine analog, is a neuroprotective agent and cognitive enhancer. Leteprinim is a hypoxanthine derivative neurotrophic agent. Leteprinim can induce brain-derived neurotrophic factor (BDNF) mRNA production following spinal cord lesions, and nerve growth factor (NGF) mRNA production in basal forebrain. Leteprinim reduces glutamate toxicity in cultured hippocampal neurons. Leteprinim increases heme-oxygenase 1 and 2 mRNA levels that play role in cellular defense against reactive oxygen species.
    Leteprinim
  • HY-120269
    CAY10512 139141-12-1
    CAY10512 is an inhibitor of NF-κB. CAY10512 can suppress the upregulation of NF-κB-sensitive proinflammatory miRNAs (miRNA-9, miRNA-125b, miRNA-146a, miRNA-155) in cerebrospinal fluid and extracellular fluid, and can be used for research on Alzheimer's disease.
    CAY10512
  • HY-120277
    TIPP 146369-65-5 98%
    TIPP is a potent and selective δ-opioid antagonist with a Ki value of 1.22 nM.
    TIPP
  • HY-120306
    HHL-6 1215093-76-7 98%
    HHL-6 can regulate the overexpression of c-Fos and BDNF proteins. HHL-6 has potent anticonvulsant and antiepileptogenic effects.
    HHL-6
  • HY-120369
    URB532 195140-79-5 98%
    URB532 is an inhibitor for fatty acid amide hydrolase (FAAH) with an IC50 of 396 nM. URB532 increases levels of arachidonic acid acetamide (AEA), palmitoylethanolamide (PEA), and oleamide (OEA) in the rat brain, and exhibits anxiolytic and analgesic effects.
    URB532
Cat. No. Product Name / Synonyms Application Reactivity